CTIX News 1.8000 05/14/2014 04:41:36 Cellceutix Corp (CTIX)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Cellceutix Corp (CTIX) 1.8000 $CTIX

Bio-Matrix Scientific Group, Inc. Sees 37% Increase In Share Price
ACCESSWIRE - Tue May 13, 9:52AM CDT
Bio-Matrix Scientific Group, Inc. (OTCPINK: BMSN) saw its share volume skyrocket on May 12th with 127,306,136 shares exchanging hands, 2.7 times higher than its three month daily average of 46,941,604 shares.

Cellceutix Confident in Its Formidable Antibiotic Arsenal
Marketwire - Mon May 12, 6:00AM CDT
Cellceutix Corporation (OTCQB: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to report this update on its clinical trial of Brilacidin(TM) for Acute Bacterial Skin and Skin Structure Infections (ABSSSI).

Psoriasis - Pipeline Review, H1 2014: 110 Companies Profiled
M2 - Thu May 08, 4:52AM CDT
Research and Markets (http://www.researchandmarkets.com/research/p6vjq8/psoriasis) has announced the addition of the "Psoriasis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Psoriasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Psoriasis and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Psoriasis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Psoriasis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Psoriasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Psoriasis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned: - 4SC AG - Acceleron Pharma, Inc. - Addex Therapeutics - Advancell - Advinus Therapeutics Ltd. - Affimed Therapeutics AG - Ajinomoto Pharmaceuticals Co., Ltd. - AlbireoPharma - Alcon, Inc. - Allozyne, Inc. - Almirall, S.A. - Amgen Inc. - Anacor Pharmaceuticals, Inc. - AnaptysBio, Inc. - AngioLab, Inc. - Apexigen, Inc. - ApoPharma Inc. - Arena Pharmaceuticals, Inc. - Argos Therapeutics, Inc. - Aurinia Pharmaceuticals Inc. - Avexxin AS - Basilea Pharmaceutica AG - Bionomics Limited - Brickell Biotech, Inc. - Can-Fite BioPharma Ltd. - Catabasis Pharmaceuticals, Inc. - Celgene Corporation - Cell Therapeutics, Inc. - Cellceutix Corporation - Celltrion, Inc. For more information visit http://www.researchandmarkets.com/research/p6vjq8/psoriasis

Tuberculosis - Pipeline Review, H1 2014: 54 Companies and 141 Drugs Profiled
M2 - Thu May 08, 4:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gtc5l6/tuberculosis) has announced the addition of the "Tuberculosis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Tuberculosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Tuberculosis and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Tuberculosis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Tuberculosis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Tuberculosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Involved: - Abera Bioscience AB - Achillion Pharmaceuticals, Inc. - Anacor Pharmaceuticals, Inc. - Archivel Farma S.L. - AstraZeneca PLC - B&C Biopharm - BioDiem Ltd - Bioversys AG - Canopus BioPharma Incorporated - Cellceutix Corporation - Chimerix, Inc. - Chongqing Zhifei Biological Products Co., Ltd. - Crucell N.V. - Dafra Pharma International Ltd. - Eisai Co., Ltd. - Eli Lilly and Company - Ensoltek Co., Ltd. - EpiVax, Inc. - FIT Biotech Oyj - Genticel - GlaxoSmithKline plc - GlobalAcorn - Globeimmune, Inc. - Imaxio - Immunitor, Inc. - ImmunoBiology Ltd. - Immunovaccine, Inc. - Johnson & Johnson - Lipotek Pty Ltd. - Medisyn Technologies, Inc. Drug Profiles: - delamanid - delamanid - V-7 Vaccine - SQ-109 - delamanid - Tuberculosis Vaccine - sutezolid - VPM-1002 - GSK-692342 - Crucell Ad-35 - RUTI Vaccine - SSI H56-IC31 Vaccine - AERAS-422 Vaccine - IMX-313-TB - Ad5Ag85A Vaccine - PMX-10072 - NasL3/HtkBCG Vaccine - MTBVAC01 - Ac2SGL Diacylated Sulfoglycolipid Vaccine - HG-85A/B - HG856-A - HG856-BCG - R32Kda-BCG Vaccine - AERAS-Capsid Vaccine - HBHA Vaccine - Streptomyces Live Vector Vaccine - rBCG(mbtB)30 Vaccine - NasL3/AM85B Vaccine - paBCG Vaccine - ORT-VAC DNA Vaccine For more information visit http://www.researchandmarkets.com/research/gt...berculosis

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Review, H1 2014: 76 Companies and 141 Drugs Profiled
M2 - Wed May 07, 12:10PM CDT
Research and Markets (http://www.researchandmarkets.com/research/d62n92/methicillinresist) has announced the addition of the "Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Companies Involved in Therapeutics Development - AIMM Therapeutics B.V. - Absynth Biologics Limited - Agilvax, Inc. - Alchemia Limited - AmpliPhi Biosciences Corporation - Aphios Corporation - Aridis Pharmaceuticals LLC - Basilea Pharmaceutica AG - Bharat Biotech International Limited - Biota Pharmaceuticals, Inc. - Cantab Biopharmaceuticals Limited - Cellceutix Corporation - Cempra, Inc. - ConjuGon, Inc. - ContraFect Corporation - CrystalGenomics, Inc. - Cubist Pharmaceuticals, Inc. - DesignMedix, Inc. - Destiny Pharma Ltd. - Dong-A Socio Holdings Co Ltd - Durata Therapeutics, Inc. - Eli Lilly and Company - Enanta Pharmaceuticals, Inc. - Ensoltek Co., Ltd. - Evolva SA - Excelimmune, Inc. - Galapagos NV - GangaGen Inc. - Genentech, Inc. - Helix BioMedix, Inc.. Drug Profiles - oritavancin disphosphate - ceftobiprole medocaril - vancomycin hydrochoride - oritavancin disphosphate - tedizolid phosphate - HT-61 - omadacycline tosylate - brilacidin - TD-1792 - AR-301 - XF-73 - CG-400549 - WCK-771 - MRX-I - levonadifloxacin - vancomycin - LTX-109 - P-128 - dalbavancin - ceftaroline fosamil - lotilibcin - BC-7013 - MRX-I - NDV-3 Vaccine - SASPject PT1.2 - KRPAM-1977X - KRPAM-1977Y - EDP-788 - SAL-200 - LCB-010371 For more information visit http://www.researchandmarkets.com/research/d6...llinresist

Hypertension - Pipeline Review, H1 2014: 48 Conipanies and 94 Drugs Profiled
M2 - Wed May 07, 8:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/h24nbf/hypertension) has announced the addition of the "Hypertension - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hypertension and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by our team. Companies Involved: - AFFiRiS AG - AbbVie Inc. - Ache Laboratorios Farmaceuticos S/A - Ahn-Gook Pharmaceutical Co., Ltd. - Ajinomoto Pharmaceuticals Co., Ltd. - Anacor Pharmaceuticals, Inc. - AngioDesign - Arromax Pharmatech, Co. Ltd. - Bayer AG - BioLineRx, Ltd. - Biocon Limited - Biolink Group AS - CJ CheilJedang Corp. - Cellceutix Corporation - Chong Kun Dang Pharmaceutical Corp. - Compugen Ltd. - Cyano Biotech GmbH - Cytokinetics, Incorporated - Daewoong Pharmaceutical Co., Ltd. - Daiichi Sankyo Company, Limited - DiaMedica Inc. - NanoForm Therapeutics Ltd. - Novartis AG - Palatin Technologies, Inc. - QUANTUM GENOMICS Corp. - RedHill Biopharma Ltd. - Sanofi - Takeda Pharmaceutical Company Limited - Toray Industries, Inc. - Torrent Pharmaceuticals Limited Drug Profiles: - azilsartan medoxomil - carvedilol CR - (rosuvastatin telmisartan) - (irbesartan atorvastatin calcium) - (rosuvastatin calcium olmesartan medoxomil) - ZV Combi - pratosartan - carvedilol CR - (rosuvastatin calcium olmesartan medoxomil) - (rosuvastatin valsartan) - CKD-825 - (losartan potassium hydrochlorothiazide amlodipine besylate) - XY-1014-KD-2 - PL-3994 - (atorvastatin calcium losartan potassium) - KD-027 - CS-3150 - (simvastatin Immediate Release amlodipine maleate Delayed Release) - LFF-269 - Potassium Magnesium Citrate - pratosartan - dextromethorphan - QGC-001 - HPT-C/D-3G - (amlodipine besylate losartan potassium) - (simvastatin losartan potassium) - (simvastatin Immediate Release amlodipine maleate Delayed Release) - (candesartan amlodipine besylate) - TAK-272 - MK-7145 IR For more information visit http://www.researchandmarkets.com/research/h2...pertension

Cohort Completed in Cellceutix Clinical Trial of Prurisol for Psoriasis
Marketwire - Wed May 07, 4:55AM CDT
Cellceutix Corporation (OTCQB: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to report that the first cohort of patients has successfully completed enrollment in the Company's clinical trial of anti-psoriasis drug candidate Prurisol(TM).

Global Oral Mucositis Clinical Trials Review 2014
M2 - Fri May 02, 6:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vxt58q/oral_mucositis) has announced the addition of the "Global Oral Mucositis Clinical Trials Review 2014" report to their offering. Oral Mucositis Global Clinical Trials Review, H1, 2014" provides data on the Oral Mucositis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Oral Mucositis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Oral Mucositis. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Espy the commercial landscape of the major Universities / Institutes / Hospitals & Companies - Amgen Inc. - Swedish Orphan Biovitrum AB - Soligenix, Inc. - Cellceutix Corporation - Jazz Pharmaceuticals plc - Endo International plc - Daewoong Co., Ltd. - CD Pharma India Private Ltd. - Biotec Pharmacon ASA - ActogeniX NV - The University of Texas M. D. Anderson Cancer Center - Children's Oncology Group - Hadassah Medical Organization - University Hospital Freiburg - Radiation Therapy Oncology Group - North Central Cancer Treatment Group - All India Institute of Medical Sciences - The University of Texas Health Science Center at San Antonio - Shahid Beheshti University - UCLA's Jonsson Comprehensive Cancer Center For more information visit http://www.researchandmarkets.com/research/vx..._mucositis

FDA Approves Clinical Trial of BrainStorm Cell Therapeutics' ALS Treatment
ACCESSWIRE - Tue Apr 29, 9:05AM CDT
BrainStorm Cell Therapeutics' (OTCQB: BCLI) stock volume skyrocketed Apr. 28, with 3,714,379 shares changing hands, more than 5 times its three-month average volume of 718,105 shares.

Top Five Daily Small Cap Trading List: InVivo Therapeutics Holding Corp, Vapor Group, Inc., Cellceutix Corp, Agenus, Magellan Petroleum Corp
PR Newswire Europe - Tue Apr 29, 9:04AM CDT
LONDON, April 29, 2014 /PRNewswire/ --

Cellceutix Corp. Reports Favorable Results on Trial of New Antibiotic
ACCESSWIRE - Mon Apr 28, 8:07AM CDT
Cellceutix Corp. (OTCQB: CTIX) enjoyed strong stock volume Apr. 25, with 180,001 shares changing hands.

Global Oral Mucositis Therapeutic Pipeline Review 2014
M2 - Mon Apr 28, 4:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/l9vr8h/oral_mucositis) has announced the addition of the "Global Oral Mucositis Therapeutic Pipeline Review 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Oral Mucositis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Oral Mucositis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Oral Mucositis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Oral Mucositis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Oral Mucositis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Involved in Therapeutics Development - Daewoong Pharmaceutical Co., Ltd. - Soligenix, Inc. - BioAlliance Pharma SA - Sucampo Pharmaceuticals, Inc. - ActogeniX NV - Alder Biopharmaceuticals Inc. - Promedior, Inc. - ProCertus BioPharm Inc. - GliaMed, Inc. - Avaxia Biologics, Inc. - Cellceutix Corporation - Vicus Therapeutics, LLC - Nephrx Corporation - Laila Pharmaceuticals Pvt. Ltd. - Applied Protein Sciences, LLC Drug Profiles - nepidermin - Lactobacillus CD2 Lozenges - sucralfate - clonidine hydrochloride ER - clazakizumab - SGX-942 - LP-004-09 - methionine - Quercetin - selenium sulfide - AG-013 - cobiprostone - GC-4403 - GM-1485 - brilacidin - PRM-151 - NX-002 - Hybrid Adenoretroviral Vectors - Regenasyn - GC-4419 - AP-002 - AP-001 - OralX - (captopril teprenone) - Anti-TNF Antibody For Oral Mucositis For more information visit http://www.researchandmarkets.com/research/l9..._mucositis

Global Candidiasis Therapeutics Pipeline Review 2014
M2 - Mon Apr 28, 4:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xr2b6p/candidiasis) has announced the addition of the "Global Candidiasis Therapeutics Pipeline Review 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Candidiasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Candidiasis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Candidiasis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Candidiasis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects Companies Involved in Therapeutics Development - Sequella, Inc. - Daiichi Sankyo Company, Limited - Merck & Co., Inc. - Novartis AG - Eisai Co., Ltd. - iCo Therapeutics Inc. - Almirall, S.A. - Basilea Pharmaceutica AG - Pacgen Life Science Corporation - NovaDigm Therapeutics, Inc. - Cellceutix Corporation - Aureogen Biosciences, Inc. - Sealife PHARMA GMBH - Panacela Labs, Inc. - Biomar Microbial Technologies Drug Profiles - posaconazole - isavuconazonium - PAC-113 - LAS-41003 - NDV-3 Vaccine - SQ-109 - PMX-30016 - amphotericin B - E-1210 - SLP-0901 - D11-2040 - Xenomycin - AUGC-15 - Compound-18545 - Compound-9403 - PMX-1502 - PMX-519 - Candida Vaccine - PMX-1408 - E-1211 - SLP-1002 - SLP-0907 - Drugs for Fungal Infections - Small Molecules for Candidiasis - Compound-14844 - Program For Women Health - PMX-70004 - PMX-1570 - PMX-1576 - PMX-1591 - PMX-1625 - Small Molecules for Aspergillosis and Candidiasis - Small Molecules for Candidiasis - Drugs for Fungal Infections - PAC-113 For more information visit http://www.researchandmarkets.com/research/xr...andidiasis

Study Shows Cellceutix Antibiotic Active Against Drug-Resistant Superbug Klebsiella Pneumoniae
Marketwire - Mon Apr 14, 5:30AM CDT
Cellceutix Corporation (OTCQB: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to report favorable results in a recently completed preclinical study evaluating its novel antibiotic compounds against specific strains of multi-drug resistant Klebsiella pneumoniae. The research, which is government funded through existing grants to research institutions, is being conducted at a major university in Texas.

Cellceutix Comments on Positive FDA Advisory Vote for Dalbavancin and Tedizolid
Marketwire - Tue Apr 01, 7:04AM CDT
Cellceutix Corporation (OTCQB: CTIX) (the "Company" is pleased to comment to its shareholders on yesterday's exciting regulatory developments and how it impacts Cellceutix's drug, Brilacidin.

Cellceutix Reports 20 Percent Enrollment Completed in Phase 2b Trial of Brilacidin as Short-Course Therapy for ABSSSI
Marketwire - Mon Mar 31, 8:25AM CDT
Cellceutix Corporation (OTCQB: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to provide shareholders an update on the status of the Company's clinical trial of its novel antibiotic Brilacidin as a treatment for Acute Bacterial Skin and Skin Structure Infections (ABSSSI). One month into the study, the trial has completed enrollment of approximately 20 percent of the total patients scheduled in the protocol.

Cellceutix Initiates Clinical Trial of Prurisol as New Treatment for Psoriasis
Marketwire - Tue Mar 25, 5:01AM CDT
Cellceutix Corporation (OTCQB: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to announce the initiation of the Company's clinical trial of its oral, small molecule drug candidate Prurisol(TM) for the treatment of psoriasis. The Prurisol(TM) tablets have been delivered to the clinical site in Miami, Florida and screening of subjects can now begin with the first dosing expected in the coming days.

Cellceutix to Initiate Psoriasis Clinical Trial
Marketwire - Fri Mar 21, 5:00AM CDT
Cellceutix Corporation (OTCQB: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, announces today that the U.S. Food and Drug Administration's ("FDA" 30-day waiting period pertaining to the Company's Investigational New Drug Application ("IND" for Prurisol(TM) has now passed. Cellceutix is moving towards the commencement of clinical trials of Prurisol(TM) as a new drug candidate for the treatment of psoriasis.

Seventh Cohort Underway in Cellceutix Clinical Trial of Kevetrin for Solid Tumors
Marketwire - Wed Mar 19, 7:42AM CDT
Cellceutix Corporation (OTCQB: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, announces today that the seventh cohort is now in progress in the Company's ongoing Phase 1 clinical trial of Kevetrin(TM), Cellceutix's novel anti-cancer drug candidate.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Eight O'Clock Adds Blonde Roast Pods to Its Lineup

Updated Category News Views 166

A lighter cup of coffee just became Eight O'Clock Coffee's newest swing at the single-serve shelf. On Nov. 19, 2026, the company said it introduced Blonde Roast K-Cup pods, a bright and smooth option aimed at drinkers who prefer a lighter roast. The product is available through Keurig.com and Amazon. That is the whole announcement, and frankly it is better to keep it that...

Continue Reading
Robert Half's Parent Support Earns Fortune Recognition

Updated Category News Views 114

A workplace award rarely moves a staffing stock by itself, and it shouldn’t. Still, Fortune naming Robert Half among its Best Workplaces for Parents for 2026 is more than decorative corporate wallpaper. In the talent business, the company’s own ability to recruit, retain and support people is part of the product. Clients hire Robert Half because they need skilled...

Continue Reading
Why Professional Collaboration May Matter More in AI

Updated Category News Views 51

Three smart professionals can still hand a client a mess when nobody owns the handoff. That unglamorous reality sits behind the Professional Collaboration Institute, or PCI, which Sarano and Brooke Kelley plan to launch in a virtual briefing on December 2. The outfit wants to turn cross-profession coordination into a teachable, measurable discipline rather than leave it...

Continue Reading
Jeff Stern Turns Travel Photography Into Full Attention

Updated Category News Views 81

A cancelled photography conference in March 2020 sent Jeff Stern toward the American Southwest, and that detour eventually became A Change of Scenery. Frankly, that origin has more grit than the usual polished creative-origin tale. While much of the world had stopped moving, Stern went alone, stood at White Pocket beneath a cobalt sky, and began reconsidering what he...

Continue Reading
Accredited Debt Relief Earns Personalized Honor in 2026

Updated Category News Views 185

A High Score Is Useful, Not a Free Pass Debt relief rankings can get awfully shiny when a company has a good week, but this one has some actual detail behind it. USA Today named Accredited Debt Relief its best provider for personalized debt relief in its 2026 review, handing the company a 94 out of 100. The ranking was published November 11 and updated November 12, and...

Continue Reading
Tigerlily Takes Its Advocacy Model to Ovarian Cancer

Updated Category News Views 236

Ovarian cancer has a nasty habit of hiding behind symptoms people are taught to shrug off. Persistent bloating or pelvic pain can look like any number of ordinary problems, and that ambiguity is exactly why practical, trusted education matters. Tigerlily Foundation's new ovarian cancer initiative is not a flashy breakthrough claim. It is a grounded attempt to help women...

Continue Reading
Titan Center Lease Gives Pocatello Retail Some Teeth

Updated Category News Views 157

A chicken sandwich lease is not usually a redevelopment thesis, yet Titan Center's new Chick-fil-A deal carries more weight than a routine restaurant announcement. Industrial Realty Group has landed a nationally recognized tenant at the entrance to a property with a long, complicated industrial past. In a smaller market, that sort of win can matter. Retail momentum is...

Continue Reading
SHEIN's EU Training Push Targets Seller Compliance Gaps

Updated Category News Views 36

Chemicals buried in a cheap handbag or kids' accessory can wreck a marketplace's credibility faster than any glossy campaign can repair it. That is the uncomfortable backdrop to SHEIN and SPEAC's November 19 session on EU chemical-safety rules for marketplace sellers. This was not a fashion trend webinar; it was a practical warning about high-risk substances, regulatory...

Continue Reading
Refund Delays Are Becoming an E-Commerce Sales Risk

Updated Category News Views 176

A returned jacket can turn into a household cash-flow problem faster than retailers seem willing to admit. Seel's new survey lands at an awkward moment for online merchants: shoppers are not merely annoyed by slow refunds; many are budgeting around them. Among 1,921 U.S. adults who had shopped online in the prior six months, 63% said waiting for a retailer to receive a...

Continue Reading
Zesty Takes Kubernetes Cost Control Into GPU Territory

Updated Category News Views 88

GPU waste has become the sort of cloud bill nobody wants to explain upstairs. A company buys scarce, expensive accelerators for AI work, then discovers that real workloads do not politely consume resources in neat, permanent blocks. Demand jumps, memory needs shift, and somebody either over-allocates to avoid trouble or under-allocates and gets ugly out-of-memory...

Continue Reading

Top 5 Most Recently Viewed Articles

Fannie Mae Reports Strong Financial Update for Third Quarter

Updated Category News Views 81

Fannie Mae Reports Impressive Third Quarter Financial Results Fannie Mae has recently announced its financial performance for the third quarter of the year, marking a significant achievement with a net income of $4 billion. This statement underscores Fannie Mae's resilience and strategic efforts in the ongoing housing market. These results were disclosed alongside the...

Continue Reading
Willdan's Innovative Energy Design Assistance for Seattle

Updated Category News Views 51

Willdan Partners with Seattle for Energy Design Innovation Willdan Group, Inc. (NASDAQ: WLDN) is thrilled to announce that it has entered into a significant four-year contract to implement the Seattle City Light Energy Design Assistance Program. This initiative is a vital step toward enhancing sustainability in the development of multifamily and commercial buildings. With...

Continue Reading
Nikola Corporation Achieves Record Hydrogen Truck Deliveries

Updated Category News Views 79

Nikola Corporation Reports Impressive Third Quarter Results Nikola Corporation (NASDAQ: NKLA) has announced its third-quarter results, showcasing remarkable progress in its hydrogen fuel cell electric vehicle (FCEV) segment. The company registered a record 88 wholesale deliveries of hydrogen FCEVs, marking a 22% increase from the previous quarter. This significant growth...

Continue Reading
Tempest Therapeutics (TPST) Faces Major Stock Decline Today

Updated Category News Views 295

Understanding the Significant Decline of Tempest Therapeutics Stock Tempest Therapeutics Inc (NASDAQ: TPST) is experiencing a notable decrease in share value today. The sharp decline follows the announcement of an all-stock acquisition of dual-CAR T programs from Factor Bioscience. Understanding the implications of this acquisition is crucial for investors and...

Continue Reading
FHU's Leadership Program Graduates First Cohort

Updated Category News Views 35

A New Dawn for School Leadership In the world of education, fresh thinking and dynamic leadership can often feel as profound as breakthroughs in any field. Today, we're celebrating a step in that direction. Freed-Hardeman University (FHU) in the heartland of Tennessee is marking a grand milestone. The university just rolled out its first cohort of graduates from the...

Continue Reading